<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764854</url>
  </required_header>
  <id_info>
    <org_study_id>D5611C00001</org_study_id>
    <nct_id>NCT01764854</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the study drug is safe, tolerable and active in&#xD;
      reducing fluid overload/weight gain between dialysis sessions for patients with End Stage&#xD;
      Renal Disease on Hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the safety, tolerability, and pharmacodynamics of the study drug in male and female&#xD;
      patients with end-stage renal disease on hemodialysis. The study consists of a 2 week&#xD;
      treatment-free run-in period where entry criteria are verified, a 4-week treatment period, of&#xD;
      which the first week of treatment will be performed as an in-patient study in a clinical&#xD;
      pharmacology unit (CPU) and the remaining three weeks of treatment will performed as an&#xD;
      out-patient study, and a 2-week treatment-free follow-up period.&#xD;
&#xD;
      Safety assessments will be performed at regular intervals and will include clinical and vital&#xD;
      signs, clinical laboratory evaluations, ECGs, and AE monitoring. Pharmacodynamic assessments&#xD;
      will include, but are not limited to, interdialytic weight gain (IDWG), blood pressure, and&#xD;
      stool sodium excretion. Pharmacokinetic assessments will include blood sampling for&#xD;
      measurement of study drug plasma concentrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Weekly Interdialytic Weight Gain (IDWG)</measure>
    <time_frame>Run-in period (Weeks -2 and -1) versus Week 4 (end of treatment)</time_frame>
    <description>Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool Sodium Content</measure>
    <time_frame>Days 1 through 7</time_frame>
    <description>The amount of sodium in a days worth of stool output</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Chronic Kidney Disease Stage 5</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>AZD1722- in patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenapanor administered in a clinical pharmacology unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- in patient</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1722 out-patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenapanor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo out-patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722 (in-patient)</intervention_name>
    <description>doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting</description>
    <arm_group_label>AZD1722- in patient</arm_group_label>
    <other_name>RDX5791</other_name>
    <other_name>Tenapanor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (in-patient)</intervention_name>
    <description>Placebo, size and color matched to experimental drug administered in a CPU</description>
    <arm_group_label>Placebo- in patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722 (out-patient)</intervention_name>
    <description>doses between 5 and 45 mg BID</description>
    <arm_group_label>AZD1722 out-patient</arm_group_label>
    <other_name>Tenapanor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, size and color matched to experimental drug</description>
    <arm_group_label>Placebo out-patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged 18 to 80 years, inclusive;&#xD;
&#xD;
          -  Body mass index between 18 and 45 kg/m2, inclusive;&#xD;
&#xD;
          -  Ambulatory (≥ 6 months) maintenance hemodialysis;&#xD;
&#xD;
          -  Stable dialysis treatment regimen 3x/week for ≥ 2 months prior to screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking diuretic medication;&#xD;
&#xD;
          -  Has a urine production of ≥ 200 ml/day (based on a 24-hour measurement starting on Day&#xD;
             -1 and completed prior to randomization);&#xD;
&#xD;
          -  Predialysis systolic BP &gt;200 mmHg or diastolic BP &gt;110 mmHg on two successive&#xD;
             occasions during the 2-week run-in period;&#xD;
&#xD;
          -  Predialysis SBP &lt; 110 mmHg on two successive occasions during the 2-week run-in period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Rosenbaum, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Clinical Research Institute</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Nephrology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <results_first_submitted>May 21, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2020</results_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZD1722- in Patient</title>
          <description>Tenapanor administered in a clinical pharmacology unit&#xD;
AZD1722 (in-patient): doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting</description>
        </group>
        <group group_id="P2">
          <title>Placebo- in Patient</title>
          <description>Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit</description>
        </group>
        <group group_id="P3">
          <title>AZD1722 Out-patient</title>
          <description>Tenapanor&#xD;
AZD1722 (out-patient): doses between 5 and 45 mg BID</description>
        </group>
        <group group_id="P4">
          <title>Placebo Out-patient</title>
          <description>Placebo&#xD;
Placebo: Placebo, size and color matched to experimental drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>relocation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD1722- in Patient</title>
          <description>Tenapanor administered in a clinical pharmacology unit&#xD;
AZD1722 (in-patient): doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting</description>
        </group>
        <group group_id="B2">
          <title>Placebo- in Patient</title>
          <description>Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit&#xD;
Placebo (in-patient): Placebo, size and color matched to experimental drug administered in a CPU</description>
        </group>
        <group group_id="B3">
          <title>AZD1722 Out-patient</title>
          <description>Tenapanor&#xD;
AZD1722 (out-patient): doses between 5 and 45 mg BID</description>
        </group>
        <group group_id="B4">
          <title>Placebo Out-patient</title>
          <description>Placebo&#xD;
Placebo: Placebo, size and color matched to experimental drug</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="8.3"/>
                    <measurement group_id="B2" value="54.4" spread="6.5"/>
                    <measurement group_id="B3" value="51.5" spread="11.5"/>
                    <measurement group_id="B4" value="49.3" spread="11.8"/>
                    <measurement group_id="B5" value="50.6" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.89" spread="9.31"/>
                    <measurement group_id="B2" value="172.05" spread="16.48"/>
                    <measurement group_id="B3" value="170.23" spread="10.80"/>
                    <measurement group_id="B4" value="170.20" spread="10.39"/>
                    <measurement group_id="B5" value="170.63" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Weekly Interdialytic Weight Gain (IDWG)</title>
        <description>Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time</description>
        <time_frame>Run-in period (Weeks -2 and -1) versus Week 4 (end of treatment)</time_frame>
        <population>The out-patient arms were the only groups that were pre-specified to be included in this analysis since the in-patient arms were only treated for one week.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1722 Out-patient</title>
            <description>Tenapanor&#xD;
AZD1722 (out-patient): doses between 5 and 45 mg BID</description>
          </group>
          <group group_id="O2">
            <title>Placebo Out-patient</title>
            <description>Placebo&#xD;
Placebo: Placebo, size and color matched to experimental drug</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Weekly Interdialytic Weight Gain (IDWG)</title>
          <description>Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time</description>
          <population>The out-patient arms were the only groups that were pre-specified to be included in this analysis since the in-patient arms were only treated for one week.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.939"/>
                    <measurement group_id="O2" value="-0.23" spread="0.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AZD1722 in-patient and Placebo in-patient are not included in this analysis since it was only a one week evaluation period and an effect was not expected. Also the size (n=8) of the group was too small to .perform this analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Sodium Content</title>
        <description>The amount of sodium in a days worth of stool output</description>
        <time_frame>Days 1 through 7</time_frame>
        <population>The in-patient arms were the only groups pre-specified to be used in this analysis since stool could only be collected in the clinical pharmacology unit (in-patient).</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1722- in Patient</title>
            <description>Tenapanor administered in a clinical pharmacology unit&#xD;
AZD1722 (in-patient): doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting</description>
          </group>
          <group group_id="O2">
            <title>Placebo- in Patient</title>
            <description>Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Sodium Content</title>
          <description>The amount of sodium in a days worth of stool output</description>
          <population>The in-patient arms were the only groups pre-specified to be used in this analysis since stool could only be collected in the clinical pharmacology unit (in-patient).</population>
          <units>mEq/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.62" spread="21.809"/>
                    <measurement group_id="O2" value="2.82" spread="2.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AZD1722 out-patient and Placebo out-patient were not included in this analysis since stool was only collected in the clinical pharmacology unit of the in-patient groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD1722- in Patient</title>
          <description>Tenapanor administered in a clinical pharmacology unit&#xD;
AZD1722 (in-patient): doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting</description>
        </group>
        <group group_id="E2">
          <title>Placebo- in Patient</title>
          <description>Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit</description>
        </group>
        <group group_id="E3">
          <title>AZD1722 Out-patient</title>
          <description>Tenapanor&#xD;
AZD1722 (out-patient): doses between 5 and 45 mg BID</description>
        </group>
        <group group_id="E4">
          <title>Placebo Out-patient</title>
          <description>Placebo&#xD;
Placebo: Placebo, size and color matched to experimental drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Development Officer</name_or_title>
      <organization>Ardelyx, Inc.</organization>
      <phone>617 513-4929</phone>
      <email>drosenbaum@ardelyx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

